At Bits&Pretzels 2025, Munich Founder event hosting 7,500 founders, investors, and industry leaders for networking MD squared launched QuickScout for Investors.

This service is designed to complement the Due Diligence Process for an investment in a MedTech Start-Up company with clinical and regulatory insights. “Investing in an innovative MedTech approach with the potential to significantly improve Healthcare can be a very compelling choice”, explains Claus Schaffrath, Founder and Managing Partner at MD squared.

“When exploring business plans during the Due Diligence Process however the implications of regulatory or clinical risks are often not sufficiently scrutinised, leading to potential significant costs of additional clinical study data and delays in the market-introduction. That’s where MD squared’s QuickScout comes in, where we assess in just one day potential Red Flags , such as the adequacy of clinical data or the validity of regulatory assumptions, which can significantly de-risk the investment. At Bit’s &Prezels we received a very positive feedback on our new multidisciplinary service, which is designed to increase confidence in an investment decision and complements our current offering to support our clients in their journey to bring their innovations to the MedTech market.”

To comment and share your thoughts join the conversation at LinkedIn!

Claus Schaffrath

Related posts:

Public Gatekeepers, Private Returns

The commercial incentives shaping EU medical device conformity assessment Key Messages The EU’s decentralized conformity assessment model relies on independent, mostly commercial notified bodies to

Read More »

Don’t hesitate to ask us your questions.

Drop an e-mail or contact us via LinkedIn

This website uses cookies to ensure you get the best experience on our website. If you want to get more information about this, please view our privacy policy page.